Trials / Unknown
UnknownNCT04725214
Anlotinib Combined With STUPP for MGMT Nonmethylated Glioblastoma
Anlotinib Combined With STUPP Protocol as First-line Regimen for MGMT Nonmethylated Glioblastoma: a Multicenter, Open-label, Single-arm, Phase II Clinical Trial
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 33 (estimated)
- Sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test the efficacy and safety of Anlotinib in combination with STUPP regimen for MGMT promoter nonmethylated glioblastoma.
Detailed description
For MGMT unmethylated glioblastoma patients undergoing STUPP regimen adjuvant therapy, during adjuvant chemotherapy, concurrent with anti-angiogenesis targeted therapy(Anlotinib capsule,d1-14).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anlotinib | Anlotinib With STUPP Regimen |
Timeline
- Start date
- 2021-01-15
- Primary completion
- 2022-12-01
- Completion
- 2023-12-01
- First posted
- 2021-01-26
- Last updated
- 2021-01-26
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04725214. Inclusion in this directory is not an endorsement.